نتایج جستجو برای: interferon beta 1b
تعداد نتایج: 269096 فیلتر نتایج به سال:
IMPORTANCE It remains unclear whether vitamin D insufficiency, which is common in individuals with multiple sclerosis (MS), has an adverse effect on MS outcomes. OBJECTIVES To determine whether serum concentrations of 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status, predict disease activity and prognosis in patients with a first event suggestive of MS (clinically isolated syndrome...
OBJECTIVE To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS) or after a short delay. METHODS Participants in BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment) were randomly assigned to receive interferon beta-1b (early treatment) or placebo (delayed treatment). After conversion to clinically definite mult...
Georgios Hadjigeorgiou, Efthimios Dardiotis, Georgios Tsivgoulis, Triantafyllos Doskas, Damianos Petrou, Nikolaos Makris, Nikolaos Vlaikidis, Thomas Thomaidis, Athanasios Kyritsis, Nikolaos Fakas, Xoulietta Treska, Clementine Karageorgiou, Stefania Sotirli, Christos Giannoulis, Dimitra Papadimitriou, Ioannis Mylonas, Evaggelos Kouremenos, George S. Vlachos, Dimitrios Georgiopoulos, Despoina Mad...
Introduction: The purpose of the study is to investigate correlation between the expanded disability status scale, depression, quality of life (QoL) and age as well as to investigate the impact of the interferon beta-1b in the QoL of MS patients and its possible depressogenic effect. Material and methods: This prospective study included 70 randomly selected patients with MS treated in the clini...
The aim of this prospective study was to evaluate therapeutic effects in a cohort of 32 patients with relapsing-remitting multiple sclerosis (RRMS) that were continuously treated with interferon beta-1b during a three-year period and to compare the results obtained with literature data available. Additionally, dropouts and side effects were assessed. The annual relapse rate at three years of tr...
OBJECTIVES Previous systematic reviews and meta-analyses of treatments in relapsing-remitting multiple sclerosis (RRMS) derived their findings from either placebo-controlled studies only or separately from head-to-head and comparative studies. The purpose of this study is to compare annualized relapse rates (ARR) of fingolimod versus all of the commonly used first-line treatments in RRMS using ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید